Table 2 Outcome measures
P. ginseng | Placebo | ||||
|---|---|---|---|---|---|
(mean ± standard deviation) | (mean ± standard deviation) | P value^ | |||
Baseline | End of treatment | Baseline | End of treatment | ||
Exacerbations | Not applicable | 0 | Not applicable | 0 | 1 |
FEV1 (L) | 1.38 ± 0.63 | 1.40 ± 0.60 | 0.83 ± 0.10 | 0.80 ± 0.06 | 0.06 |
FVC (L) | 2.79 ± 0.59 | 3.00 ± 0.50 | 2.33 ± 0.36 | 2.40 ± 0.46 | 0.11 |
FEV1/FVC | 0.48 ± 0.13 | 0.40 ± 0.10 | 0.36 ± 0.06 | 0.30 ± 0.06 | 0.14 |
SGRQ | 37.20 ± 12.85 | 32.20 ± 12.20 | 45.80 ± 10.54 | 34.40 ± 8.20 | 0.74 |
CAT (total score) | 17.0 ± 6.32 | 16.20 ± 5.40 | 17.20 ± 4.87 | 14.40 ± 2.70 | 0.67 |
SF-36–General health | 40.0 ± 23.18 | 48.00 ± 20.70 | 37.0 ± 14.40 | 39.0 ± 18.50 | 0.49 |
SF-36–Mental health | 79.20 ± 17.75 | 82.40 ± 12.10 | 86.40 ± 7.26 | 89.60 ± 6.60 | 0.49 |
6MWT (m) | 518.20 ± 10.01 | 502.80 ± 29.0 | 453.20 ± 60.27 | 453.0 ± 20.50 | 0.01* |